ENFN241220C15000
- 0.00
- 0.000.00%
Enfusion Newsroom
Enfusion To Present at Upcoming Investor Events
An Intrinsic Calculation For Enfusion, Inc. (NYSE:ENFN) Suggests It's 38% Undervalued
There May Be Some Bright Spots In Enfusion's (NYSE:ENFN) Earnings
Morgan Stanley Maintains Enfusion(ENFN.US) With Buy Rating, Maintains Target Price $11
Stifel Maintains Enfusion(ENFN.US) With Buy Rating, Raises Target Price to $11
Enfusion | 10-Q: Q3 2024 Earnings Report
Enfusion: Strong Client Acquisitions and Strategic Positioning Drive Buy Rating
Enfusion Price Target Raised to $11 From $10 at Stifel
Enfusion, Inc. (ENFN) Q3 2024 Earnings Call Transcript Summary
Enfusion, Inc. (ENFN) Q3 2024 Earnings Call Transcript
William Blair Maintains Enfusion(ENFN.US) With Buy Rating
William Blair Remains a Buy on Enfusion (ENFN)
Express News | Enfusion Inc - Q3 Rev $51.2 Mln
Enfusion Q3 Adjusted Earnings, Revenue Increase; 2024 Revenue Guidance Narrowed
Express News | Enfusion Narrows FY2024 Sales Guidance From $200.00M-210.00M to $202.00M-205.00M VS Est. 204.8M
Enfusion Non-GAAP EPS of $0.05 Misses by $0.01, Revenue of $51.17M Misses by $1M
Earnings Preview: Enfusion to Report Financial Results Pre-market on November 04
FTV Capital Named to Inc.'s Founder-Friendly Investors List for Fourth Consecutive Year
Enfusion, Inc.'s (NYSE:ENFN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Enfusion, Inc. (ENFN): This Fintech Stock Is Riding the AI Wave Higher